The expression levels of miR-181d, RBP2 and NF-κB p65 were assessed in 42 newly diagnosed CML-CP patients and 15 CML-BP patients. The gene discussed is NFKB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.